dotty_mcleod_interview_17-11-16
13th September 2017
|By Phico
“dotty_mcleod_interview_17-11-16”.
“dotty_mcleod_interview_17-11-16”.
Ian joined BGF in September 2011 and is responsible for BGF’s varied portfolio of early stage investments across the UK. Before BGF, Ian was the CFO of Quotient Sciences, a provider of specialised drug development services to the global pharmaceutical sector. He also spent 10 years at 3i, where he completed over 20 investments across a range of sectors and represented 3i on the board of over 30 companies, supporting their growth and realising value via trade sale, flotation and refinancing. He started his career as an engineer at Jaguar Cars, developing autonomous vehicles.
Richard Nagle is an experienced biotech executive and has built and developed business solutions across the international biopharma sector. His focus on accelerating product development has led to successful company exits or IPO, including recent CEO and Board Director of Immune Regulation (now Revolo Biotherapeutics) an innovative biotechnology platform business focused on regulating the immune system which successfully raised $50m in 2020 from Morningside Ventures. Previously, Richard served as Non-Executive Director of Peptinnovate and as CEO of a number of successful drug delivery, biotechnology and medical device businesses. He was also a Director of IMS Health and Quintiles (now IQVIA).
Andrew is a Chartered Accountant with wide industry experience including healthcare, particularly in financial restructuring, equity fundraising and corporate acquisitions and disposals. Andrew was the Finance Director of Colchester Hospital where he led the strategic plan to consolidate services on one site. Before becoming an FD, he spent 15 years in the advisory departments of Grant Thornton and Deloitte working on restructuring and corporate finance assignments.
David Beadle has over 25 years’ experience in the healthcare and finance industries and brings a wealth of knowledge in investment banking, finance and life sciences. David started his career working in the pharmaceutical industry for Schwarz Pharma and Schering AG in marketing and strategic development, where he was part of the global development group for oncology.
He then moved to investment banking where he built and led highly ranked healthcare equity research teams both globally and across Europe. He first joined Hoare-Govett and then moved to UBS AG investment bank where he was a Managing Director in the equities division. He was a leading and highly ranked equity research analyst in the healthcare sector for over 10 years. At UBS, David was the lead analyst on several corporate finance projects, including IPOs and M&A.
David has been a non-executive Director to several companies in the healthcare and biotechnology space and has consulted for many others regarding scientific, corporate finance and business development strategies. David was a founding partner of Napa Capital, a corporate finance advisory company, working with several clients regarding financing projects and corporate strategy.
Mark is a Consultant Microbiologist, Head of Research and Development in Microbiology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds (Leeds Institute of Molecular Medicine), and is the Lead on Clostridium difficile for Public Health England (PHE) and Medical Advisor to National Infection Prevention and Control Lead (NHS Improvement), England. He is a member of the Medical Research Council’s Infections and Immunity Board, and the Scientific Advisory Board for the EU Innovative Medicines Initiative’s COMBACTE-NET consortium.
Microbiologist with over 10 years’ experience in the biotech and anti-infectives industry; Biocontrol Ltd (Ampliphi Biosciences)
Robert has over 30 years’ experience in big pharma, including from 1989 to end 2004 as Director of Global Licensing at AstraZeneca. Bob is a non-executive director of Epistem Ltd. He gained his Ph.D. in biochemistry from King’s College, London, and completed two post-doctoral fellowships in the US at Dartmouth Medical School and MIT.
Dr Martin has more than 25 years’ experience in providing life science and biotechnology companies counsel on a range of strategic, management and funding issues, including as Chairman of anti-infectives company, NeuTec Pharma plc, where he played a pivotal role in guiding the company’s sale to Novartis for over £300M.
Dr Fairhead has over 20 years’ experience directing research teams in a variety of disciplines and has led Phico in developing SASPject technology from a concept through a Phase I clinical trial. Prior to her scientific career, Heather worked in sales and marketing in a wide range of industries.